Background and objectives: Smoking is considered a significant risk factor in periodontitis. The pathogenesis of periodontal disease may be affected by alterations of the inflammatory response by smoke. Interleukin-1 (IL-1β), an effective pro-inflammatory cytokine have been associated with the immunopathology of periodontitis. The aim of this study was to assess the levels of IL-1β in saliva from smokers and non-smokers with chronic periodontitis and periodontally healthy controls. Materials and methods: Gingival index, Plaque index, probing pocket depth, clinical attachment level, bleeding on probing were assessed in 84 subjects who were equally divided in to three groups. group I periodontally healthy non-smoking subjects ; group II non-smokers with chronic periodontitis; group III smokers with chronic periodontitis; Enzyme Linked Immunosorbent Assay (ELISA) test was used for quantification of Interleukin (IL)- 1β in the saliva samples. Statistical analysis were performed with SPSS version 22.0. Results: Interleukin-1β level in saliva was significantly higher in smoker than in nonsmokers with chronic periodontitis and the controls (P˂ 0.001). In subjects with chronic periodontitis, a significant correlation existed between CAL and IL-β (r= 0.313, p= 0.052) among non-smokers; there was also a highly significant positive correlation between, CAL and IL-β (r= 0.310, p= 0.051), BOP and IL-β (r= 0.333, p= 0.05) among smokers. Conclusion: Salivary IL-1β level were significantly elevated in periodontitis patients. Smokers with chronic periodontitis exhibited a highly significant increase in salivary IL-1β levels. Hence, this reflects the impact of smoking on immune response and its role in the pathogenesis of periodontal disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.